Test-retest variability of adenosine A2A binding in the human brain with 11C-TMSX and PET

EJNMMI Research

Volumn 4, Issue 1, 2014, Pages

  Naganawa, Mika ^a,b   Mishina, Masahiro ^b,c   Sakata, Muneyuki ^b   Oda, Keiichi ^d   Hiura, Mikio ^e   Ishii, Kenji ^b   Ishiwata, Kiichi ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^e HOSEI UNIVERSITY   (Japan)

Author keywords

11C TMSX; Adenosine A2A receptor; Positron emission tomography; Reproducibility

Indexed keywords

ADENOSINE A2A RECEPTOR; CARBON 11;

ARTICLE; BINDING AFFINITY; BRAIN CORTEX; HUMAN; IMAGE ANALYSIS; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; RADIOCHEMISTRY; RADIOGRAPHY; TEST RETEST RELIABILITY; TMSX PROCEDURE;

EID: 84938090736     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-014-0076-9     Document Type: Article

References (33)

1. 2areceptor ligand.J Nucl Med 2000, 41:345–354.
2. 2Areceptors in rats.Synapse 2001, 42:164–176.
3. 2Areceptors in the brain.Synapse 2008, 62:671–681.
4. 11C]TMSX for myocardial imaging by positron emission tomography: a first human study.Ann Nucl Med 2003, 17:457–462.
5. 11C]TMSX.Synapse 2005, 55:133–136.
6. 11C]TMSX PET.Synapse 2007, 61:778–784.
7. 11C]TMSX and positron emission tomography.Eur J Nucl Med Mol Imaging 2007, 34:679–687.
8. 11C]TMSX PET in the striata of Parkinson's disease patients.PLoS One 2011, 6:e17338.
9. 2Areceptors.Synapse 2012, 66:832–839.
10. 11C]SCH442416.Eur J Nucl Med Mol Imaging 2005, 32:405–413.
11. 2Areceptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect.J Nucl Med 2008, 49:1183–1188.
12. 2Areceptors by positron emission tomography.Ann Nucl Med 2003, 17:205–211.
13. Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, Ishii K, Orihara H, Fukuda H, Satoh T, Kitamura K, Tanaka K, Takahashi S: Performance evaluation of a large axial field-of-view PET scanner: SET-2400 W.Ann Nucl Med 1997, 11:307–313.
14. 11C]flumazenil PET.Ann Nucl Med 2000, 14:193–198.
15. Svenningsson P, Hall H, Sedvall G, Fredholm BB: Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study.Synapse 1997, 27:322–335.
16. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE: Consensus nomenclature for in vivo imaging of reversibly binding radioligands.J Cereb Blood Flow Metab 2007, 27:1533–1539.
17. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman DR: Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects.J Cereb Blood Flow Metab 1990, 10:740–747.
18. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL: Distribution volume ratios without blood sampling from graphical analysis of PET data.J Cereb Blood Flow Metab 1996, 16:834–840.
19. Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability.Psychol Bull 1979, 86:420–428.
20. 11C]DASB and positron emission tomography in humans: modeling considerations.J Cereb Blood Flow Metab 2007, 27:205–217.
21. 11C-DASB in healthy humans: reproducibility and comparison of methods.J Nucl Med 2006, 47:815–826.
22. Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.Behav Res Methods 2007, 39:175–191.
23. 11C]TMSX brain PET study.J Cereb Blood Flow Metab 2013, 33:1394–1401.
24. 18 F]CPFPX by CYP1A2: implications for bolus/infusion PET studies.Nucl Med Biol 2006, 33:891–898.
25. 11C]FLB 457: reproducibility studies.Synapse 2011, 65:35–40.
26. 18 F]CPFPX and PET.Eur J Nucl Med Mol Imaging 2007, 34:1061–1070.
27. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN: Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited.J Cereb Blood Flow Metab 2010, 30:46–50.
28. 11C]GSK931145, a PET ligand for the glycine transporter type 1.Synapse 2011, 65:1319–1332.
29. 18 F-CPFPX and PET.J Nucl Med 2012, 53:1723–1729.
30. 3H]-CGS 21680 in the rat brain.Naunyn Schmiedebergs Arch Pharmacol 1996, 354:539–541.
31. 11C]MRB for assessment of occupancy of norepinephrine transporters: studies with atomoxetine in non-human primates.Neuroimage 2011, 56:268–279.
32. 123I-MNI-420 in humans.J Nucl Med 2013, 54:1760–1767.
33. 18 F]MK-6577 in humans.Synapse 2015, 69:33–40.